Novartis India will hold a meeting of the Board of Directors of the Company on 12 May 2026.

Novartis India announced that Sandra Martyres (DIN: 00798406), Independent Director, shall be completing her second and final term as an Independent Director of the Company on 18 April 2026. Accordingly, she ceases to be the Director of the Company w.e.f. close of business hours of 18 April 2026.Powered by Capital Market - Live News

The board of Novartis India at its meeting held on 27 March 2026 has approved the appointment of Gowree Gokhale (DIN: 09351661) as an Additional Director (designated as Non-Executive and Independent Director) on the Board of the Company for a period of 5 (five) consecutive years with effect from 01 April 2026 up to 31 March 2031, subject to approval of the Members of the Company. Powered by Capital Market - Live News

Net profit of Novartis India declined 36.78% to Rs 16.09 crore in the quarter ended December 2025 as against Rs 25.45 crore during the previous quarter ended December 2024. Sales declined 7.63% to Rs 85.90 crore in the quarter ended December 2025 as against Rs 93.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales85.9093.00 -8 OPM %26.0327.51 - PBDT30.1335.82 -16 PBT29.6535.29 -16 NP16.0925.45 -37 Powered by Capital Market - Live News

Novartis India will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live News